c-myc oncogene expression in estrogen-dependent and -independent breast cancer
Shiu, R.P.; Watson, P.H.; Dubik, D.
Clinical Chemistry 39(2): 353-355
1993
ISSN/ISBN: 0009-9147 PMID: 8432027 Document Number: 408094
We demonstrate that c-myc gene expression is essential for growth of breast cancer cells. It also plays an important role in the progression of human breast cancer. c-myc gene amplification may be important for cancer cell invasion, but perhaps not essential for nodal metastasis. We also provide compelling evidence that the c-myc oncogene is an estrogen target gene in hormone-responsive breast cancer. Hormonal progression of breast cancer could be brought about by the enhanced expression of the c-myc gene, with gene amplification and enhanced c-myc mRNA stability being two major mechanisms involved.
Document emailed within 1 workday
Related Documents
Hou, X.; Li, J.J.; Chen, W.; Li, S.A. 1996: Estrogen-induced proto-oncogene and suppressor gene expression in the hamster kidney: significance for estrogen carcinogenesis Cancer Research 56(11): 2616-2620Nishimura, R.; Nagao, K.; Miyayama, H.; Matsuda, M.; Baba, K.; Matsuoka, Y.; Ueno, Y.; Yamashita, H.; Nomura, K.; Ichiguchi, O. 1991: Expression of ras oncogene p21 in relation to prognostic factors of human breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 18(13): 2271-2275
Castles, C.G.; Fuqua, S.A.; Klotz, D.M.; Hill, S.M. 1993: Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line Cancer Research 53(24): 5934-5939
Ferguson, A.T.; Lapidus, R.G.; Baylin, S.B.; Davidson, N.E. 1995: Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression Cancer Research 55(11): 2279-2283
Díez Gibert, O.; Machuca, I.; Sebastián, M.A.; Rosel, P.; Navarro, M.A. 1996: Expression of pS2 protein in breast cancer and its relationship with estrogen and progesterone receptors Medicina Clinica 107(3): 90-92
Li, H.; Wojciechowski, W.; Dell'Agnola, C.; Lopez, N.E.; Espinoza-Delgado, I. 2006: IFN-gamma and T-bet expression in human dendritic cells from normal donors and cancer patients is controlled through mechanisms involving ERK-1/2-dependent and IL-12-independent pathways Journal of Immunology 177(6): 3554-3563
Jakubícková, L.; Baráthová, M.; Pastoreková, S.; Pastorek, J.; Gibadulinová, A. 2005: Expression of S100P gene in cervical carcinoma cells is independent of E7 human papillomavirus oncogene Acta Virologica 49(2): 133-137
Joe, A.K.; Memeo, L.; Mckoy, J.; Mansukhani, M.; Liu, H.; Avila-Bront, A.; Romero, J.; Li, H.; Troxel, A.; Hibshoosh, H. 2005: Cyclin D1 overexpression is associated with estrogen receptor expression in Caucasian but not African-American breast cancer Anticancer Research 25(1a): 273-281
Deng, W.-h.; Wu, Y.-y.; Luo, L.-h.; Wang, S.; Tang, W.-q.; Zhang, Y.-f. 2003: Expression of estrogen sulfotransferase in breast tissues and the regulation of ESTmRNA by estrogen Zhonghua Yi Xue Za Zhi 83(21): 1891-1894
Zukerberg, L.R.; Yang, W.I.; Gadd, M.; Thor, A.D.; Koerner, F.C.; Schmidt, E.V.; Arnold, A. 1995: Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology Inc 8(5): 560-567
Dargent, D. 2000: Estrogen replacement therapy in patients in remission after treatment for estrogen dependent cancer. Certainties are still lacking Gynecologie Obstetrique and Fertilite 28(6): 427-428
Paciotti, G.F.; Tamarkin, L. 1988: Interleukin-2 differentially affects the proliferation of a hormone-dependent and a hormone-independent human breast cancer cell line in vitro and in vivo Anticancer Research 8(6): 1233-1239
Hou, Y-feng.; Yuan, S-tao.; Li, H-cheng.; Wu, J.; Lu, J-song.; Lu, L-juan.; Liu, G.; Shen, Z-zhou.; Ding, J.; Shao, Z-min. 2005: In vitro study of the effects of estrogen receptor beta expression on the biological behavior of a human breast cancer cell line Zhonghua Zhong Liu Za Zhi 27(7): 389-392
Spitkovsky, D.; Aengeneyndt, F.; Braspenning, J.; von Knebel Doeberitz, M. 1996: p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene Oncogene 13(5): 1027-1035
Zeng, X.; Yao, Z. 2003: Relationship between expression of somatostatin receptors subtype 2 mRNA and estrogen and progesterone receptors in breast cancer Chinese Medical Journal 116(12): 1850-1853
Hsieh, T.-C.; Wu, J.M. 2008: Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and gamma-tocotrienol in estrogen receptor-positive MCF-7 breast cancer cells International Journal of Oncology 33(4): 851-859
Avci, N.; Deligonul, A.; Tolunay, S.; Cubukcu, E.; Fatih Olmez, O.; Ulas, A.; Hartavi, M.; Kurt, E.; Evrensel, T. 2015: Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 20(1): 45-49
Masiuk, M. 2006: Expression and intranuclear distribution of nucleolin in estrogen receptor-negative and estrogen receptor-positive breast cancers in women measured by laser scanning cytometry Annales Academiae Medicae Stetinensis 52(2): 23-32
Brück, P.; Vilches Cisneros, N.; Ramos López, E.; Barboza Quintana, O.; Ancer Rodríguez, J.ús.; Flores Gutiérrez, J.P. 2006: Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients Ginecologia y Obstetricia de Mexico 74(10): 516-522
Chlebowski, R.T.; Rohan, T.E.; Manson, J.E.; Aragaki, A.K.; Kaunitz, A.; Stefanick, M.L.; Simon, M.S.; Johnson, K.C.; Wactawski-Wende, J.; O'Sullivan, M.J.; Adams-Campbell, L.L.; Nassir, R.; Lessin, L.S.; Prentice, R.L. 2015: Breast Cancer After use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data from 2 Women's Health Initiative Randomized Clinical Trials JAMA Oncology 1(3): 296-305